The limited dispensation of other antidiabetic classes in our study, like GLP-1 receptor agonists and SGLT2 inhibitors, could be partially explained by the fact that we only included newly diagnosed and treated T2D patients, and that not all the classes of GLP-1 receptor agonists were commercialized during the study period. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.